|
|
||||||||
Ann Thorac Surg 2004;78:1522
© 2004 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, University Hospital of Groningen, Groningen, the Netherlands
b Department of Biomedical Engineering, Groningen University Medical Center, Groningen, the Netherlands
* Address reprint requests to Dr Boonstra, Department of Cardiothoracic Surgery, Groningen University Medical Center, Hanzeplein 1, 9713 EZ Groningen, the Netherlands (E-mail: p.w.boonstra@thorax.azg.nl).
| The first 20% of the full text of this article appears below. |
Clopidogrel,also known as Plavix, is an inhibitor of adenosine diphosphateinduced platelet aggregation (thienopyridine derivate). In combination with aspirin, which blocks the thromboxane-mediated pathway, it is recommended as the standard therapy for prevention of coronary artery stent thrombosis [1]. These two drugs ensure that platelet function will be inhibited and that stent thrombosis will be prevented. As a consequence of the widespread use of these drugs in treating acute coronary syndromes and using percutaneous coronary interventions, patients will have an increased risk of major bleeding [2]. In this issue of The Annals, Chu and associates prospectively assessed hemostasis after operations performed in 80
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |